Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

NCT04002674 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Georgetown University

Collaborators